Tandem Diabetes Care, Inc.
Clinical trials sponsored by Tandem Diabetes Care, Inc., explained in plain language.
Medical device company making insulin pumps for diabetes.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New insulin pump software tested in kids as young as 2
Disease control CompletedThis study is checking how safe and effective an updated insulin pump system (Control-IQ 1.5) is for children ages 2 to 6 with type 1 diabetes. About 144 kids will use the pump for a year while researchers track dangerous low blood sugar events and diabetic ketoacidosis. The goal…
Sponsor: Tandem Diabetes Care, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New insulin set aims to last a full week for type 1 diabetes
Disease control CompletedThis study tests a new insulin infusion set designed to last up to 7 days for people with type 1 diabetes. Twenty adults currently using a Tandem insulin pump and Dexcom CGM will try the SteadiSet at home. The goal is to see if the set can survive a full week without causing high…
Sponsor: Tandem Diabetes Care, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New insulin pump software aims to cut dangerous low blood sugar events
Disease control CompletedThis study tested an updated version of the Control-IQ system, which automatically adjusts insulin delivery for people with type 1 diabetes. Sixty-six adults and adolescents used the new software along with a continuous glucose monitor for several weeks. The main goal was to see …
Sponsor: Tandem Diabetes Care, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New tech aims to simplify diabetes management
Disease control CompletedThis study tested a smart insulin system called Control-IQ+ in 319 adults with type 2 diabetes who use insulin. The goal was to see if the technology helps control blood sugar better than standard care. Participants used the system for a period, and researchers measured changes i…
Sponsor: Tandem Diabetes Care, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New insulin system tested in hotel setting for type 1 diabetes
Disease control CompletedThis study tested a new insulin delivery system called Tandem Freedom in 10 adults with type 1 diabetes. Participants used their usual system at home for a week, then switched to the new system in a supervised hotel setting. The goal was to check safety and how well it controls b…
Sponsor: Tandem Diabetes Care, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New insulin system tested in hotel study – no severe events reported
Disease control CompletedThis small study tested a new insulin delivery system called Tandem Freedom in 10 adults with type 1 diabetes. Participants first used their usual system at home for a week, then switched to Tandem Freedom in a supervised hotel setting. The main goals were to check for severe low…
Sponsor: Tandem Diabetes Care, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New insulin set aims to last a full week – no more Every-Other-Day changes?
Disease control CompletedThis study tested a new insulin infusion set designed to be worn for up to 7 days instead of the usual 2-3 days. 260 adults with type 1 diabetes used the set at home for 12 wear periods. The goal was to see if the set could safely deliver insulin for a full week without causing h…
Sponsor: Tandem Diabetes Care, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC